Sadly, some of the strongest characters that stand out in the books didn't make it into any of the Harry Potter movies.

H.C. Wainwright analyst Andrew Fein raised the firm’s price target on Catalyst Pharmaceuticals (CPRX) to $35 from $30 and keeps a Buy rating on ...

Harry Potter introduced viewers to a world of wizards, spells, and fantastical creatures. Based on a book series of the same ...

Catalyst Pharmaceuticals Inc. (NASDAQ:CPRX) entered into a settlement agreement with Teva Pharmaceuticals Industries Ltd ...

The Harry Potter series is getting adapted all over again, and there are plenty of things it should do differently this time. By expanding from about one movie per book into perhaps more than a season ...

More than 2,800 Texans are getting abortion pills through the mail from out-of-state every month, prompting a lawsuit and ...

Stocks like Rail Vikas Nigam, CESC, Dhanlaxmi Bank, Jubilant Ingrevia, Adani Green Energy, Archean Chemical Industries, Century Enka, Bank of India, Prataap Snacks, Power Grid Corporation of India, ...

Catalyst stock gains 17% as it settles Firdapse patent litigation with Teva protecting the drug's exclusivity in the United ...

The stake sale is being conducted through an accelerated book-building process ... in the US markets. Lupin is one of the first ANDA applicants and is eligible for 180 days of shared generic ...

Prince Harry and Meghan Markle’s new Netflix documentary, Polo, had viewers saying neigh-xt! Their latest project for the ...

As India marks a decade of its Act East Policy, Odisha is a vital hub, with its grand shoreline, foundational ports, and its historic maritime ties across southeast Asia, to unlock opportunities and ...

Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for ...